KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Medtronic (MDT) over the last 12 years, with Q4 2025 value amounting to $1.3 billion.

  • Medtronic's Cash & Equivalents fell 803.44% to $1.3 billion in Q4 2025 from the same period last year, while for Oct 2025 it was $1.3 billion, marking a year-over-year decrease of 803.44%. This contributed to the annual value of $2.2 billion for FY2025, which is 7274.14% up from last year.
  • Medtronic's Cash & Equivalents amounted to $1.3 billion in Q4 2025, which was down 803.44% from $1.3 billion recorded in Q3 2025.
  • In the past 5 years, Medtronic's Cash & Equivalents ranged from a high of $5.1 billion in Q1 2021 and a low of $1.2 billion during Q1 2025
  • Moreover, its 5-year median value for Cash & Equivalents was $1.9 billion (2022), whereas its average is $2.5 billion.
  • Per our database at Business Quant, Medtronic's Cash & Equivalents tumbled by 7284.59% in 2023 and then surged by 7274.14% in 2025.
  • Quarter analysis of 5 years shows Medtronic's Cash & Equivalents stood at $2.9 billion in 2021, then soared by 66.48% to $4.8 billion in 2022, then plummeted by 72.85% to $1.3 billion in 2023, then rose by 6.33% to $1.4 billion in 2024, then fell by 8.03% to $1.3 billion in 2025.
  • Its Cash & Equivalents was $1.3 billion in Q4 2025, compared to $1.3 billion in Q3 2025 and $2.2 billion in Q2 2025.